TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infant approximately 2 months of age (42 days to 90 days), inclusive~* In good health~Exclusion Criteria:~* Prior administration of any pneumococcal vaccine~* Known hypersensitivity to any component of the pneumococcal conjugate vaccine or any diphtheria toxoid-containing vaccine~* Known or suspected impairment of immunological function~* History of congenital or acquired immunodeficiency (eg, splenomegaly)~* Mother has documented human immunodeficiency virus (HIV) infection~* Mother has documented hepatitis B surface antigen-positive test result~* Known or history of functional or anatomic asplenia~* History of failure to thrive~* History of a coagulation disorder~* History of autoimmune disease~* Known neurologic or cognitive behavioral disorder~* Expects to require systemic corticosteroids within 30 days after each vaccination during the trial~* Prior administration of a blood transfusion or blood products, including immunoglobulin~* Participated in another clinical trial of an investigational product~* History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- V114 Lot 1 (Type: EXPERIMENTAL): Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
- V114 Lot 2 (Type: EXPERIMENTAL): Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Chronic rejection~1. Bronchiolitis obliterans diagnosed by bronchiolitis obliterans syndrome and \> 20% decline from the individual patient's best FEV1 is observed~2. Recipient of a double or single lung transplant~3. Receiving immunosuppressive treatment according to institutional standards~Exclusion criteria:~1. Active invasive bacterial, viral or fungal infection~2. Current mechanical ventilation~3. Pregnant or breast-feeding woman~4. Known hypersensitivity to cyclosporine A~5. Serum creatinine value of more than 265 μmol/L (3 mg/dL) or chronic dialysis~6. Receipt of an investigational drug as part of a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Aerosol Cyclosporine (Type: EXPERIMENTAL): Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
- Conventional oral immune suppression (Type: ACTIVE_COMPARATOR): Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Neonates in the neonatal unit with an infection requiring treatment with vancomycin as determined by the treating physician.~Exclusion Criteria:~* Infants with a corrected gestational age \< 25 weeks.~* Allergy to vancomycin or other glycopeptide antibiotic~* Vancomycin administered within the previous 72 hours~* Renal impairment~* Prior enrolment in the study~* Need for drug that is incompatible with vancomycin (if no other IV line is available)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Intermittent infusion of vancomycin (Type: NO_INTERVENTION): Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
- Continuous infusion of vancomycin (Type: ACTIVE_COMPARATOR): A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older at the time of the Screening Visit.~* Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus.~* Patient has a diagnosis of DGP with no history or evidence of mechanical obstruction, symptoms for at least 3 consecutive months preceding the Screening Visit, and delayed gastric emptying of solids documented within 2 years of the Screening Visit.~* Patient has a normal EGD either during the Screening Period or within 2 years of the Screening Visit, with no evidence of structural or organic disease that may explain the patient's gastroduodenal symptoms.~* Patient is compliant with eDiary completion.~* Patient agrees to refrain from making any new, major lifestyle changes.~* Patient is fluent and literate in English.~Exclusion Criteria:~* Patient has a history or current symptoms of any organic or structural disease that, in the opinion of the investigator, can cause abdominal pain or discomfort and may confound the assessment of DGP symptoms.~* Patients with rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or bulimia.~* Patient is currently using a gastric electric stimulator or has had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the Screening Visit.~* Patient has been hospitalized within the 2 months prior to the Screening Visit for uncontrolled diabetes mellitus, DGP, or associated malnutrition.~* Patient reports significant diarrhea during the four weeks prior to the Screening Visit, or more than 2 days during either week of the Pretreatment Period.~* Patient has had surgery of the GI tract any time before the Screening Visit, an appendectomy or cholecystectomy during the 3 months before the Screening Visit, non-GI surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or other major non-GI surgery during the 30 days before the Screening Visit.~* Patient has a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo once in the morning and once in the evening.
- IW-9179 QD AM + Placebo QD PM (Type: EXPERIMENTAL): IW-9179 once in the morning and placebo once in the evening.
- Placebo QD AM + IW-9179 QD PM (Type: EXPERIMENTAL): Placebo once in the morning and IW-9179 once in the evening.
- IW-9179 BID (Type: EXPERIMENTAL): IW-9179 once in the morning and once in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Males and females, age 7 to 18 years~Onset of psychotic symptoms before 13th birthday and a DSM-IV diagnosis of either schizophrenia, schizoaffective disorder, MDI syndrome, or psychosis NOS (not otherwise specified).~Current significant impairment due to the illness (current psychotic symptoms, decline of functioning academically and socially, significant discomfort due to psychotic symptoms).~Failure of two prior trials with antipsychotic medications (either typical or atypical) used at adequate doses (greater than or equal to 100 mg/day in chlorpromazine equivalents) and for adequate duration (at least 4 weeks, unless terminated due to intolerable side effects). Failure is defined as either insufficient response with persistence of symptoms significantly impairing child's functioning, according to child's and parental reports and medical and school records, or intolerable side effects to drugs other than clozapine and olanzapine.~Subjects may be included if their previous trial(s) of olanzapine failed to reach the dose of 20. mg/day or a duration of fewer than four weeks.~Subjects may be included if their previous trial(s) of clozapine failed to reach the dose of 200. mg/day or a duration of fewer than six weeks.~Comorbid psychiatric disorders in the past 12 months are permitted as long as not clinically significant.~EXCLUSION CRITERIA:~Prepsychotic full-scale IQ less than 70.~Unstable major neurological or medical conditions.~Current pregnancy or plan to become pregnant during the first three months (the duration of the study) in woman of childbearing age; breast-feeding in woman with infants.~DSM-IV substance abuse or dependence in the past 6 months.~True non-responders to either olanzapine or clozapine. True non-response is defined as: a) intolerance to either of the medications preventing an adequate trial, or b) only minimal (less than 20%) benefit with the adequate trial of either of the medications. Adequate trial constitutes at least 8 weeks of the medication with the dose of 20 mg on olanzapine or 200 mg of clozapine.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: ACTIVE_COMPARATOR): None
- Clozapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of ES with age greater than or equal to 14 years and weight greater than or equal to 30 kgs in World Health Organisation (WHO) functional class II and III attending our congenital clinic were invited to participate in the study~Exclusion Criteria:~* WHO class IV,~* congestive heart failure or had PCWP \> 15mmHg,~* left ventricular ejection fraction \<40%,~* atrial fibrillation,~* patent ductus arteriosus,~* complex congenital heart defects,~* restrictive lung disease(total lung capacity \< 70% of predicted), obstructive lung disease ( forced expiratory volume in 1 second \[FEV1\] \< 70% of predicted with FEV1/ Forced vital capacity \[FVC\] \< 60%),~* previously diagnosed coronary artery disease requiring nitrate therapy,~* abnormal biochemical profile and~* hypersensitivity to PDE- 5 inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chiropractic Manipulation and Medical Care for Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age: ≥ 18 years of age~* Ability to read and write English~* Experiencing a new episode of low back pain (LBP) with onset in the past 3 months~* Oswestry Disability Index score between 20-70 points (0-100 scale)~* Numeric pain rating score between 3-8 points (0-10 scale)~Exclusion Criteria:~* Prior history of lumbar spine surgery~* History of unstable spondylolisthesis, spinal stenosis, or scoliosis \> 20°~* Signs or symptoms suggestive of nerve root tension and/or neurological deficit in the lower extremity~* History of metastatic cancer, osteoporosis, long-term corticosteroid use, or any other red flags of serious illness including the following: unexplained weight loss of \>10% of body weight, spinal pain associated with fever, and severe night pain unrelieved by medication~* Receiving any physical therapy, chiropractic therapy, or any other manual therapy for this episode of LBP (within the past 3 months)~* Receiving any on-going medical care for this episode of low back pain~* Current use of opiate or other prescription medications for low back pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Manual Manipulation (Type: EXPERIMENTAL): Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
- Mechanical Manipulation (Type: EXPERIMENTAL): Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
- Standard Medical Care (Type: ACTIVE_COMPARATOR): Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients, \>/= 6 years of age~* Confirmed diagnosis of cystic fibrosis (CF)~* Receiving Pulmozyme once daily chronically for treatment of CF for at least 6 months prior to screening~* Percent predicted FEV1 \>/= 40% at screening based on the Wang (males \< 18 years, females \< 16 years) or Hankinson (males \>/= 18 years, females \>/= 16 years) standardized equations~* Able to reproducibly perform spirometry testing and comply with study assessments~Exclusion Criteria:~* An acute respiratory infection or pulmonary exacerbation within 4 weeks prior to randomization~* Initiation of any new chronic therapy (e.g. inhaled corticosteroids, inhaled oral antibiotics, high-dose ibuprofen, hypertonic saline, ivacaftor) for respiratory disease within 4 weeks prior to randomization~* Changes in chest physiotherapy schedule within 4 weeks prior to randomization~* Hospitalization within 4 weeks prior to randomization~* Planned hospitalization during the 6-week study~* History of organ transplantation~* Participation in an investigational drug or device study within 30 day prior to screening

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eRapid Nebulizer (Type: EXPERIMENTAL): Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
- Jet Nebulizer (Type: ACTIVE_COMPARATOR): Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ischemic stroke with symptoms of neurological deficits.~2. Aged 18 to 80 years（including the critical value）.~3. NIH Stroke Scale（NIHSS）scores of 4 to 25（including the critical value）.~4. Treatment within 4.5 hours after stroke onset.~5. The symptoms of stroke last at least 30 minutes without significant improvement before treatment.~6. CT showed negative or signs of early infarction.~7. Informed Consent Form signed by the patients or family (legal representatives) must be provided.~Exclusion Criteria:~1. Patients with premorbid modified Rankin Scale (mRS) score ≥2~2. CT showed multiple infarctions（low density\> 1/3 cerebral hemisphere）.~3. Transient ischemic attack.~4. Epileptic seizure after stroke.~5. Intracranial tumor, arteriovenous malformation and aneurysm.~6. Iatrogenic Stroke.~7. Planned for thrombectomy.~8. Cardioembolism and atrial fibrillation.~9. Myocardial infarction history within 3 months.~10. Severe cerebral trauma or stroke history within 3 months.~11. Patients with systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg after anti-hypertension treatment.~12. Intracranial hemorrhage or subarachnoid hemorrhage on baseline.~13. Active visceral hemorrhage.~14. Patients with intracerebral hemorrhage history.~15. Patients with diabetic retinopathy history.~16. Puncture in 1 week which can not be oppressed.~17. Major surgery or severe trauma within 2 weeks.~18. Intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days.~19. Heparin treatment within 48h and increased APTT is above ULN.~20. Using of oral anticoagulant drugs and PT \>15s or INR \>1.7.~21. High risk of acute hemorrhage include platelet count\<10\^9/L.~22. Using of thrombin inhibitors or factor Xa inhibitor with abnormal results of sensitive laboratory examination.~23. Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L.~24. Pregnancy, lactating or menstrual women.~25. The investigator believes that the patient is not suitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Recombinant human urokinase (rhPro-UK)
- Group B (Type: ACTIVE_COMPARATOR): Alteplase(rt-PA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Patients between 18 and 80 years old with type 2 diabetes and insufficient glycemic control \[glycosylated hemoglobin (HbA1c 7% to 10%)\] despite therapy with a sulfonylurea drug~Exclusion criteria:~Myocardial infarction,stroke or transient ischaemic attack in last 6 months Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs in the past 3 months Impaired hepatic function Severe renal impairment Current treatment with systemic steroids Change in thyroid hormone dosage Hereditary galactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 (Type: ACTIVE_COMPARATOR): 5 mg orally (po) once daily
- Placebo (Type: PLACEBO_COMPARATOR): one tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be of non-childbearing potential and female patients must have a negative pregnancy test at the Screening Visit~* Histologically and/or cytologically confirmed cancer with ECOG ≤2~* Life expectancy of ≥ 3 months~* Assigned to receive the first cycle of a new multi-day chemotherapy regimen including the daily administration of cytotoxic agent(s) with the emetogenic potential of level 3-5 (Hesketh Classification) on 3-5 days~Exclusion Criteria:~* Hypersensitivity to adhesive plasters~* Contraindications to 5-HT3 receptor antagonists~* Clinically relevant abnormal laboratory values or hepatic, renal, infectious, neurological or psychiatric disorders or any other major systemic illness at the discretion of the Investigator~* Any cause for nausea and vomiting other than CINV~* Clinically relevant abnormal ECG parameters~* Concomitant radiotherapy of total body, brain or upper abdomen within one week of study entry or planned during the study~* A patient taking a medication to control the symptoms of a brain tumour, brain metastasis or seizure disorder

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete